Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)

No Thumbnail Available

Date

2022-01-01

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

https://hdl.handle.net/11443/2335
 http://dx.doi.org/10.1016/j.annonc.2022.07.1876

Collections

WOS

Endorsement

Review

Supplemented By

Referenced By